Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimers disease. The CompanyÔÇÖs products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimers brain. The SavaDx, is an early-stage program focused on detecting the presence of Alzheimers disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is also developing SavaDx is a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The CompanyÔÇÖs scientific approach for the treatment of Alzheimers disease seeks to simultaneously progress both neurodegeneration and neuroinflammation.
Number of employees : 11 people.
|Armistice Capital LLC ||2,164,000||
|The Vanguard Group, Inc. ||1,864,160||
|First Eagle Investment Management LLC ||1,695,395||
|Remi Barbier ||1,083,721||
|SSgA Funds Management, Inc. ||939,086||
|BlackRock Fund Advisors ||938,234||
|Sanford R. Robertson ||920,095||
|CaaS Capital Management LP ||687,260||
|Nantahala Capital Management LLC ||647,053||
|Geode Capital Management LLC ||638,473||
|Company contact information|
Cassava Sciences, Inc.
7801 North Capital of Texas Highway
Austin, TX 78731
Phone : +1.512.501.2444
Fax : +1.512.614.0414
Web : http://www.cassavasciences.com
Sector Bio Therapeutic Drugs
Connections : Cassava Sciences, Inc.